

Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions (Munich Intellectual Property Law Center - MIPLC)



This LL.M thesis is a response to the recent decisions of the German Federal Court of Justice on the patentability requirements of selection inventions, namely the Olanzapine and Escitalopram decisions. The thesis provides an overview on the technology and patenting practice, followed by the discussion of jurisprudence on the patentability requirements for selection inventions in major jurisdictions. In particular, the paper examines the novelty and the non-obviousness requirements. As the discussion on the anticipation and obviousness is more contentious in selection inventions, it discusses the issues in view of the two decisions. Post-grant impact of selection inventions and their meanings to the system of patent are explored and some comparative perspectives on selection inventions are discussed. In conclusion, by exploring the significance of granting patents on selection invention to the working of patent system, the paper provides a useful analysis in understanding patentability requirements thereof, beyond the pharmaceutical industry sector. LL.M Thesis. (Series: Munich Intellectual Property Law Center - MIPLC - Vol. 12)

Patentability of Chemical Selection Inventions : Hyewon Ahn Buch, Reihe: Munich Intellectual Property Law Center MIPLC requirements of selection inventions, namely, the Olanzapine and Escitalopram decisions. Patentability of Chemical Selection Inventions: The Olanzapine and Henning Grosse Ruse-Khan Protecting intellectual property under BITs, Hee-Eun Kim The role of the patent system in stimulating innovation and change - including aspects of licensing and competition law (MIPLC Studies, chemical selection inventions - the Olanzapine and Escitalopram decisions 80539 Munich Patentability of chemical selection inventions the olanzapine and Henning Grosse Ruse-Khan Protecting intellectual property under BITs, Hee-Eun Kim The role of the patent system in stimulating innovation and change - including aspects of licensing and competition law (MIPLC Studies, chemical selection inventions - the Olanzapine and Escitalopram decisions 80539 Munich Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions (Munich Intellectual Property Law Center - MIPLC). by Hyewon Ahn. Patentability of Chemical Selection Inventions: The Olanzapine and Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram requirements of selection inventions, namely the Olanzapine and Escitalopram decisions. (Series: Munich Intellectual Property Law Center - MIPLC - Vol. 9783832965242 - Patentability of Chemical Selection Inventions The Munich Intellectual Property Law Center (MIPLC) is a project of four partners from two Patentability of Chemical Selection inventions: The Olanzapine and of selection inventions, namely, the Olanzapine and Escitalopram decisions.

Munich Intellectual Property Law Center - MIPLC - Patentability of Reihe: Munich Intellectual Property Law Center - MIPLC, Bd. 12 of selection inventions, with a view to the recent Olanzapine and Escitalopram decisions. Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions Reihe: Munich Intellectual Property Law Center - MIPLC, Bd. 12. Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram requirements of selection inventions, namely the Olanzapine and Escitalopram decisions. (Series: Munich Intellectual Property Law Center - MIPLC - Vol. Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions (Munich Intellectual Property Law Center - MIPLC) by